Japan · Delayed Price · Currency is JPY Fuji Pharma Statistics
Total Valuation
Fuji Pharma has a market cap or net worth of JPY 48.50 billion. The enterprise value is 67.39 billion.
| Market Cap | 48.50B |
| Enterprise Value | 67.39B |
Important Dates
The last earnings date was Tuesday, November 10, 2026.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | Sep 29, 2026 |
Share Statistics
Fuji Pharma has 26.12 million shares outstanding. The number of shares has increased by 4.35% in one year.
| Current Share Class | 26.12M |
| Shares Outstanding | 26.12M |
| Shares Change (YoY) | +4.35% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 37.23% |
| Owned by Institutions (%) | 18.15% |
| Float | 14.40M |
Valuation Ratios
The trailing PE ratio is 16.70 and the forward PE ratio is 10.23.
| PE Ratio | 16.70 |
| Forward PE | 10.23 |
| PS Ratio | 0.78 |
| PB Ratio | 0.92 |
| P/TBV Ratio | 1.25 |
| P/FCF Ratio | 11.88 |
| P/OCF Ratio | 7.86 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.38, with an EV/FCF ratio of 16.51.
| EV / Earnings | 23.80 |
| EV / Sales | 1.08 |
| EV / EBITDA | 6.38 |
| EV / EBIT | 10.60 |
| EV / FCF | 16.51 |
Financial Position
The company has a current ratio of 1.65, with a Debt / Equity ratio of 0.54.
| Current Ratio | 1.65 |
| Quick Ratio | 0.92 |
| Debt / Equity | 0.54 |
| Debt / EBITDA | 2.69 |
| Debt / FCF | 6.95 |
| Interest Coverage | 15.89 |
Financial Efficiency
Return on equity (ROE) is 5.70% and return on invested capital (ROIC) is 8.02%.
| Return on Equity (ROE) | 5.70% |
| Return on Assets (ROA) | 4.14% |
| Return on Invested Capital (ROIC) | 8.02% |
| Return on Capital Employed (ROCE) | 9.73% |
| Weighted Average Cost of Capital (WACC) | 4.30% |
| Revenue Per Employee | 35.45M |
| Profits Per Employee | 1.61M |
| Employee Count | 1,760 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.74 |
Taxes
In the past 12 months, Fuji Pharma has paid 324.00 million in taxes.
| Income Tax | 324.00M |
| Effective Tax Rate | 10.27% |
Stock Price Statistics
The stock price has increased by +12.41% in the last 52 weeks. The beta is 0.33, so Fuji Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | +12.41% |
| 50-Day Moving Average | 1,809.70 |
| 200-Day Moving Average | 2,054.96 |
| Relative Strength Index (RSI) | 51.96 |
| Average Volume (20 Days) | 158,450 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Fuji Pharma had revenue of JPY 62.39 billion and earned 2.83 billion in profits. Earnings per share was 111.18.
| Revenue | 62.39B |
| Gross Profit | 24.32B |
| Operating Income | 6.36B |
| Pretax Income | 3.16B |
| Net Income | 2.83B |
| EBITDA | 10.56B |
| EBIT | 6.36B |
| Earnings Per Share (EPS) | 111.18 |
Balance Sheet
The company has 9.50 billion in cash and 28.37 billion in debt, with a net cash position of -18.88 billion or -722.71 per share.
| Cash & Cash Equivalents | 9.50B |
| Total Debt | 28.37B |
| Net Cash | -18.88B |
| Net Cash Per Share | -722.71 |
| Equity (Book Value) | 52.45B |
| Book Value Per Share | 2,007.35 |
| Working Capital | 21.39B |
Cash Flow
In the last 12 months, operating cash flow was 6.17 billion and capital expenditures -2.09 billion, giving a free cash flow of 4.08 billion.
| Operating Cash Flow | 6.17B |
| Capital Expenditures | -2.09B |
| Depreciation & Amortization | 4.21B |
| Net Borrowing | -1.98B |
| Free Cash Flow | 4.08B |
| FCF Per Share | 156.28 |
Margins
Gross margin is 38.98%, with operating and profit margins of 10.19% and 4.54%.
| Gross Margin | 38.98% |
| Operating Margin | 10.19% |
| Pretax Margin | 5.06% |
| Profit Margin | 4.54% |
| EBITDA Margin | 16.93% |
| EBIT Margin | 10.19% |
| FCF Margin | 6.54% |
Dividends & Yields
This stock pays an annual dividend of 49.00, which amounts to a dividend yield of 2.64%.
| Dividend Per Share | 49.00 |
| Dividend Yield | 2.64% |
| Dividend Growth (YoY) | 14.29% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 43.27% |
| FCF Payout Ratio | 33.27% |
| Buyback Yield | -4.35% |
| Shareholder Yield | -1.71% |
| Earnings Yield | 5.99% |
| FCF Yield | 8.42% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Analyst Forecast
The average price target for Fuji Pharma is 2,950.00, which is 58.86% higher than the current price. The consensus rating is "Buy".
| Price Target | 2,950.00 |
| Price Target Difference | 58.86% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 7.29% |
| EPS Growth Forecast (3Y) | 30.73% |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Jun 27, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Fuji Pharma has an Altman Z-Score of 2.31 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.31 |
| Piotroski F-Score | 7 |